Please use this identifier to cite or link to this item:
Title: Access to orphan drugs and quality of life in rare disease
Authors: Abbas, Amar
Vella Szijj, Janis
Serracino-Inglott, Anthony
Keywords: Rare diseases -- Diagnosis
Rare diseases -- Patients -- European Union countries
Rare diseases -- Patients -- Unites States
Quality of life -- Health aspects -- Evaluation
Orphan drugs -- Prices
Pharmaceutical policy
Issue Date: 2018-10
Publisher: University of Malta. Department of Pharmacy
Citation: Abbas, A., Vella Szijj, J., & Serracino Inglott, A. (2018, October). Access to orphan drugs and quality of life in rare disease. Poster session presented at the ACCP Global Conference on Clinical Pharmacy, Seattle, Washington, USA.
Abstract: A poster presentation regarding access to orphan drugs and quality of life in rare disease. Introduction: Over 7000 rare diseases (RD) affect around 300 million patients worldwide. More than 80% of RDs are genetic and appear early in life, resulting in a 30% mortality rate in children diagnosed before their fifth birthday. To date, there has been no locally conducted study about the healthcare needs of people living with RDs. Research on RDs focuses on treatment and care of RDs with limited focus on health related quality of life and accessibility to Orphan Drugs (ODs). Aims: To analyse what regulations and policies related to OD accessibility are available in Malta and internationally. To assess the Quality of Life of RD patients.
Appears in Collections:Scholarly Works - FacM&SPha

Files in This Item:
File Description SizeFormat 
Access_to_orphan_drugs_and_quality_of_life_in_rare_disease_2018.pdf353.16 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.